To date, no validated biomarker has been identified to help clinicians determine which patients with advanced melanoma are more likely to benefit from ICI therapy, although emerging tools, such as the interferon gamma (IFN-γ) signature and circulating tumour DNA (ct DNA), hold promise for improving the response prediction and patient stratification. This evidence concerns the gene IFNG and neoplasm.